J.P. Morgan Biotech Confab Live Chat

SAN FRANCISCO ( TheStreet) -- Welcome to the J.P. Morgan Biotech Confab Live Chat.

I'm here to offer my take on the first day of the biotech sector's largest and most important investor conference. And of course, I'm happy to answer your biotech stock investing questions.

This year's J.P. Morgan conference should be renamed the Hepatitis C Hoedown for the buzz being generated about Bristol-Myers Squibb's ( BMY) $2.5 billion acquisition of Inhibitex ( INHX) and the resulting speculative mania that is gripping Idenix Pharmaceuticals ( IDIX) and Achillion Pharmaceuticals ( ACHN). Both stocks are seen as potential takeover targets, too, but how likely is that or is it just wishful thinking?

I spent my day listening to presentations by Celgene ( CELG), Onyx Pharmaceuticals ( ONXX), Amarin ( AMRN), Vivus, ( VVUS) and Dendreon ( DNDN).

--Written by Adam Feuerstein in San Francisco.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Health Care Stocks: A Year in Review and Predictions for 2015

Health Care Stocks: A Year in Review and Predictions for 2015

'Fast Money' Recap: Next Stop, S&P 2,100?

'Fast Money' Recap: Next Stop, S&P 2,100?

Cramer: Every Which Way But Short

Cramer: Every Which Way But Short

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout